International non- proprietary name: Cetuximab  Brand name: Erbitux  Target; Format: Erbitux EGFR; Chimeric

International non- proprietary name: Cetuximab

 Brand name: Erbitux

 Target; Format: Erbitux EGFR; Chimeric IgG1

Indication first approved or reviewed:  Colorectal cancer

First EU approval year: 2004

 First US approved: 2004

 

"Looking for a Similar Assignment? Get Expert Help at an Amazing Discount!"